Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer

The rearrangement of anaplastic lymphoma kinase (ALK) occurs in 3%‐5% of patients with non–small cell lung cancer (NSCLC) and confers sensitivity to ALK–tyrosine kinase inhibitors (TKIs). For the treatment of patients with ALK‐rearranged NSCLC, various additional ALK‐TKIs have been developed. Ceriti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakashita, Takuya, Yanagitani, Noriko, Koike, Sumie, Low, Siew‐Kee, Takagi, Satoshi, Baba, Satoko, Takeuchi, Kengo, Nishio, Makoto, Fujita, Naoya, Katayama, Ryohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633314/
https://www.ncbi.nlm.nih.gov/pubmed/35950895
http://dx.doi.org/10.1111/cas.15529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633314/
https://www.ncbi.nlm.nih.gov/pubmed/35950895
http://dx.doi.org/10.1111/cas.15529

Ejemplares similares